AbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire global rights to GUB014295, a ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with ...

In this randomized controlled trial, insulin alfa efsitora (efsitora) demonstrated noninferiority to degludec in reducing ...

Whether you have type 2 diabetes, obesity or just a few extra pounds that you’d like some help shedding, chances are you’re ...

In recent years, the landscape of diabetes and weight management has been significantly altered by the rise of glucagon-like peptide-1 (GLP-1) receptor agonists. These medications, initially developed ...

Consumers taking GLP-1 drugs like Ozempic will need to adapt their shopping habits and diets, opening opportunities for food ...

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...

Researchers assess whether GLP-1 receptor agonists increase the risk of suicide, self-harm, or suicidal ideation in type 2 ...

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...

A recent genetic study has provided new insights into how glucagon-like peptide-1 (GLP-1) receptor agonists aid weight loss.

Age differences are seen in the efficacy of treatments for type 2 diabetes, according to study results published in the Journal of the AMA.